RxDoctor Payments DataLook up a doctor →

Jorge Calzada, MD

Retina Specialist · Southaven, MSNPI 1538154117

Payments from drug & device makers

$1,960,464in general payments, 2019–2025

Across 1,069 payments — averaging $1833.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$743K
  • Roche TCRC, Inc.$608K
  • Boehringer Ingelheim International GmbH$223K
  • Genentech, Inc.$153K
  • AstraZeneca$118K
  • Apellis Pharmaceuticals, Inc.$61K
  • plus $54K from 28 others
$2,354in research payments, 2019–2025

Across 13 payments — averaging $181.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K

What the payments were for

  • Consulting fees$35,19030%
  • Speaking & faculty fees$60,09552%
  • Travel & lodging$9,0108%
  • Food & beverage$10,9029%
  • Education$5070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,732,982
Medicare patients
1,011
Services billed
76,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost45$18,255
CombiganBrimonidine Tartrate/Timolol45$15,508
RestasisCyclosporine17$9,757
Tobramycin-DexamethasoneTobramycin/Dexamethasone195$8,406
RhopressaNetarsudil Mesylate14$5,785
Prednisolone Acetate69$2,803
SimbrinzaBrinzolamide/Brimonidine Tart13$2,580
Brimonidine Tartrate74$2,480
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,226
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat127$1,967
Ketorolac Tromethamine68$1,906
Travoprost13$1,881
Latanoprost271$1,776
ValacyclovirValacyclovir Hcl15$946
Timolol Maleate40$512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$1,293$43,520107 claims
Aerie Pharmaceuticals, Inc.Rhopressa$17$5,78514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other retina specialist in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →